Related Experiment Video
Updated: Oct 22, 2025
LAD-Ligation: A Murine Model of Myocardial Infarction
Published on: October 14, 2009
Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
Niels Grote Beverborg1, Daniela Später2,3, Ralph Knöll4,5
1Department of Cardiology University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Insights
Antisense oligonucleotides targeting phospholamban (PLN) mRNA show promise for treating heart failure (HF). This novel therapy improved cardiac function and survival rates in preclinical models of genetic and ischemia-driven HF.
Area of Science:
- Cardiology
- Molecular Medicine
- Pharmacology
Background:
- Heart failure (HF) is a significant global health burden with limited treatment options.
- Dysfunctional calcium (Ca2+) handling is a hallmark of HF pathophysiology.
- Targeting Ca2+ regulatory proteins presents a viable therapeutic strategy.
Purpose of the Study:
- To investigate antisense oligonucleotides (ASOs) targeting phospholamban (PLN) mRNA as a potential HF treatment.
- To evaluate the efficacy of PLN-ASO in preclinical models of genetic and acquired heart failure.
Main Methods:
- Development and administration of PLN-ASO in murine models of dilated cardiomyopathy (DCM) and in rats with myocardial infarction.
- Assessment of PLN protein aggregation, cardiac function, and survival rates.
- Evaluation of left ventricular remodeling and contractility.
Main Results:
- PLN-ASO prevented PLN protein aggregation and reversed cardiac dysfunction in a PLN R14del DCM model, increasing survival by threefold.
- PLN-ASO treatment improved cardiac function in a separate genetic DCM model (Cspr3/Mlp-/-).
- In rats with myocardial infarction, PLN-ASO mitigated left ventricular dilatation and enhanced contractility.
Conclusions:
- Antisense inhibition of PLN is a promising therapeutic strategy for diverse HF etiologies.
- PLN-ASO demonstrates efficacy in preclinical models of genetic cardiomyopathy and ischemia-induced HF.
- This approach offers a novel therapeutic avenue for heart failure management.
Abstract:
Heart failure (HF) is a major cause of morbidity and mortality worldwide, highlighting an urgent need for novel treatment options, despite recent improvements. Aberrant Ca2+ handling is a key feature of HF pathophysiology. Restoring the Ca2+ regulating machinery is an attractive therapeutic strategy supported by genetic and pharmacological proof of concept studies. Here, we study antisense oligonucleotides (ASOs) as a therapeutic modality, interfering with the PLN/SERCA2a interaction by targeting Pln mRNA for downregulation in the heart of murine HF models. Mice harboring the PLN R14del pathogenic variant recapitulate the human dilated cardiomyopathy (DCM) phenotype; subcutaneous administration of PLN-ASO prevents PLN protein aggregation, cardiac dysfunction, and leads to a 3-fold increase in survival rate. In another genetic DCM mouse model, unrelated to PLN (Cspr3/Mlp-/-), PLN-ASO also reverses the HF phenotype. Finally, in rats with myocardial infarction, PLN-ASO treatment prevents progression of left ventricular dilatation and improves left ventricular contractility. Thus, our data establish that antisense inhibition of PLN is an effective strategy in preclinical models of genetic cardiomyopathy as well as ischemia driven HF.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System